Last reviewed · How we verify
Standard blood components
Standard blood components restore normal blood function by replacing deficient or dysfunctional cellular and protein elements.
Standard blood components restore normal blood function by replacing deficient or dysfunctional cellular and protein elements. Used for Acute blood loss and hemorrhage, Anemia requiring transfusion, Thrombocytopenia.
At a glance
| Generic name | Standard blood components |
|---|---|
| Sponsor | University of Washington |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Standard blood components include red blood cells, platelets, plasma, and clotting factors that are transfused to patients with deficiencies due to bleeding, anemia, or bone marrow disorders. These components restore oxygen-carrying capacity, hemostasis, and essential plasma proteins necessary for normal physiological function.
Approved indications
- Acute blood loss and hemorrhage
- Anemia requiring transfusion
- Thrombocytopenia
- Coagulation factor deficiency
- Support during surgery or trauma
Common side effects
- Transfusion reaction (acute hemolytic)
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Transfusion-related acute lung injury (TRALI)
- Infection transmission risk
- Iron overload (with chronic transfusion)
Key clinical trials
- "Effect of Pre-Spinal Mindfulness-Based Breathing Exercise on Hemodynamic Response in Elective Cesarean Section" (NA)
- Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
- MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence (NA)
- INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (PHASE3)
- Impact of Ambulatory Continuous Monitoring Using Remote Monitoring Medicine Within Patient's Care Pathway Following Colorectal Surgery (CONTACT-GRECCAR 21) (NA)
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (PHASE3)
- Feasibility of Video Gaming Technology for Arm Recovery Early Post-stroke (NA)
- Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard blood components CI brief — competitive landscape report
- Standard blood components updates RSS · CI watch RSS
- University of Washington portfolio CI